Milton Ault III Sells 20,397 Shares of Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 20,397 shares of the stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $2.32, for a total value of $47,321.04. Following the sale, the director directly owned 8,260 shares of the company’s stock, valued at $19,163.20. The trade was a 71.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alzamend Neuro Stock Down 6.4%

Alzamend Neuro stock opened at $2.18 on Friday. Alzamend Neuro, Inc. has a twelve month low of $2.06 and a twelve month high of $17.10. The stock has a 50 day moving average of $2.40 and a two-hundred day moving average of $3.85.

Analysts Set New Price Targets

Several research firms have recently commented on ALZN. Ascendiant Capital Markets reduced their price target on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, September 25th. Wall Street Zen cut Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Alzamend Neuro in a report on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Alzamend Neuro currently has an average rating of “Hold” and an average price target of $42.00.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.